Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

McKesson's FoxMeyer purchase $400 mil.-$600 mil. below first bid -- FoxMeyer suit.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

MCKESSON's FOXMEYER PURCHASE $400-$600 MIL. BELOW FIRST BID, FOXMEYER MAINTAINS in seeking $400 mil. in damages from the wholesaler and 10 drug companies for "a conspiracy of events orchestrated" to drive FoxMeyer's wholesaling business into bankruptcy. In a suit filed Jan. 10 in Dallas state court by holding company FoxMeyer Health, the company alleges that McKesson "led [FoxMeyer] to believe" that it would offer "an amount in the range of $400-$600 mil. for FoxMeyer Health's equity interest in FoxMeyer Corp." in August 1995. FoxMeyer decided to sell off its distribution arm in May 1995.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Table

View full table

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS086582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By